Drug intelligence / Profile preview

RSVI-305 + RSVI-306

Development stage: Unknown
Lead developer: RosVivo Therapeutics

Overview

**RSVI-305 + RSVI-306** is an investigational combination therapy developed by RosVivo Therapeutics, Inc., consisting of two proprietary candidates, RSVI-305 and RSVI-306, likely targeting unmet needs in viral or chronic diseases. Limited public data exists on their specific mechanisms, but they are part of RosVivo's pipeline alongside RSVI-301 and RSVI-307, with RSVI-301 noted for miRNA-based action reducing insulin resistance in diabetes with low side effects during repeated infusions. No detailed mechanism of action, primary indications, or clinical results are disclosed for RSVI-305 or RSVI-306; they appear early-stage with no reported trials or approvals.[2][15]

Other names: RSVI-307RSVI307RSVI 307

Beyond the preview

Go deeper on RSVI-305 + RSVI-306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSVI-305 + RSVI-306.

Explore the full profile